Brokerages Set Agenus Inc. (NASDAQ:AGEN) Target Price at $10.50

Shares of Agenus Inc. (NASDAQ:AGEN) have been given a consensus rating of “Hold” by the six brokerages that are presently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $10.50.

Several brokerages recently issued reports on AGEN. HC Wainwright downgraded Agenus from a “buy” rating to a “neutral” rating and decreased their target price for the company from $40.00 to $9.00 in a research note on Thursday, July 18th. William Blair lowered Agenus from an “outperform” rating to a “market perform” rating in a research note on Thursday, July 18th. Baird R W lowered Agenus from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 19th. Robert W. Baird lowered Agenus from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $35.00 to $8.00 in a research report on Friday, July 19th. Finally, StockNews.com lowered Agenus from a “hold” rating to a “sell” rating in a research report on Monday, August 12th.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets raised its stake in shares of Agenus by 81.3% in the first quarter. BNP Paribas Financial Markets now owns 188,414 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 84,477 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Agenus by 13.7% during the first quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock worth $19,953,000 after purchasing an additional 4,134,232 shares in the last quarter. Acadian Asset Management LLC increased its position in shares of Agenus by 1,959.9% during the first quarter. Acadian Asset Management LLC now owns 757,397 shares of the biotechnology company’s stock worth $439,000 after purchasing an additional 720,629 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Agenus by 52.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company’s stock worth $208,000 after buying an additional 123,058 shares during the last quarter. Finally, Ovata Capital Management Ltd purchased a new stake in Agenus in the 2nd quarter valued at approximately $670,000. 61.46% of the stock is currently owned by hedge funds and other institutional investors.

Agenus Stock Performance

AGEN stock opened at $5.64 on Friday. Agenus has a fifty-two week low of $4.41 and a fifty-two week high of $27.20. The business’s 50-day moving average is $7.59 and its two-hundred day moving average is $10.68. The company has a market cap of $118.43 million, a price-to-earnings ratio of -0.44 and a beta of 1.36.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($2.52) EPS for the quarter, missing the consensus estimate of ($1.33) by ($1.19). The firm had revenue of $23.51 million during the quarter, compared to analysts’ expectations of $64.73 million. During the same quarter in the prior year, the business earned ($4.00) earnings per share. Equities analysts predict that Agenus will post -10.87 earnings per share for the current year.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.